PharmaEssentia Corp.

As of June 30, 2026, PharmaEssentia Corp. carries a market capitalization of 500.63B, placing it among publicly traded companies globally. Its enterprise value stands at 477.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PharmaEssentia Corp.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, PharmaEssentia Corp. has 414.43M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, PharmaEssentia Corp. maintains a current ratio of 5.28, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, PharmaEssentia Corp. recorded 1.39B in income tax expense.

As of the close on October 22, 2026, PharmaEssentia Corp.'s stock has gained approximately 150.34% over the past 52 weeks. The 50-day moving average sits at 1,292.20, while the 200-day moving average is 892.27.

As of June 30, 2026, PharmaEssentia Corp. holds 24.49B in cash and equivalents against 1.02B in total debt, resulting in a net debt position of -24.42B. Total book value stands at 36.82B, with working capital of 27.22B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

PharmaEssentia Corp.'s most recent stock split took place on July 9, 2026 with a 485:538 split ratio.